Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis

Vascul Pharmacol. 2024 Mar:154:107249. doi: 10.1016/j.vph.2023.107249. Epub 2023 Dec 7.

Abstract

The prevalence of non-alcoholic fatty liver disease (NAFLD) and atherosclerosis remain high, which is primarily due to widespread adoption of a western diet and sedentary lifestyle. NAFLD, together with advanced forms of this disease such as non-alcoholic steatohepatitis (NASH) and cirrhosis, are closely associated with atherosclerotic-cardiovascular disease (ASCVD). In this review, we discussed the association between NAFLD and atherosclerosis and expounded on the common molecular biomarkers underpinning the pathogenesis of both NAFLD and atherosclerosis. Furthermore, we have summarized the mode of function and potential clinical utility of existing drugs in the context of these diseases.

Keywords: Association; Atherosclerosis; Biomarkers; NAFLD; NASH.

Publication types

  • Review

MeSH terms

  • Atherosclerosis* / pathology
  • Biomarkers
  • Fibrosis
  • Humans
  • Liver / pathology
  • Liver Cirrhosis
  • Non-alcoholic Fatty Liver Disease* / complications
  • Non-alcoholic Fatty Liver Disease* / diagnosis
  • Non-alcoholic Fatty Liver Disease* / epidemiology

Substances

  • Biomarkers